Current treatment status-Undergoing active treatment-No response - Page 2 of 19 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Aug 22, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of pembrolizumab (Keytruda) plus GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) as second-line therapy for patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab plus GVD combination is safe and highly effective...

Read More

Evaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.

Evaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.

Posted by on Aug 22, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term safety and effectiveness of tandem chimeric antigen receptor (tCAR) T-cell therapy for patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that tCAR T-cell therapy resulted in long-term remission rates with manageable side effects for these patients. Some...

Read More

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Posted by on Aug 15, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including non-Hodgkin lymphoma (NHL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial...

Read More

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Posted by on Aug 8, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of dual chimeric antigen receptor (CAR) T-cell therapy for patients with recurrent or hard-to-treat B-cell non-Hodgkin lymphoma (NHL). This study found that this treatment was safe and effective for these patients. Some background B-cell non-Hodgkin’s lymphoma (NHL) is one of...

Read More

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma/leukemia?

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma/leukemia?

Posted by on Jul 31, 2021 in Leukemia | 0 comments

In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was...

Read More

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma?

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma?

Posted by on Jul 31, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was associated...

Read More

Evaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL

Evaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL

Posted by on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of loncastuximab tesirine (Zynlonta) for patients with diffuse large B-cell lymphoma (DLBCL) that returned or stopped responding to treatment. This study concluded that this treatment was safe and effective for these patients. Some background DLBCL is one of the most common types of...

Read More

Evaluating CAR T-cell therapy before stem cell transplantation for patients with B-cell ALL

Evaluating CAR T-cell therapy before stem cell transplantation for patients with B-cell ALL

Posted by on Jul 11, 2021 in Leukemia | 0 comments

In a nutshell This study evaluated the safety and effectiveness of CAR T-cell therapy versus chemotherapy before a stem cell transplant (SCT) for patients with recurrent or non-responsive B-cell acute lymphoblastic lymphoma (B-ALL). The authors concluded that CAR T-cell therapy followed by SCT was safe and effective for these patients. Some background...

Read More

Inotuzumab ozogamicin with bosutinib for relapsed/refractory Philadelphia chromosome-positive ALL or lymphoid blast phase of CML

Inotuzumab ozogamicin with bosutinib for relapsed/refractory Philadelphia chromosome-positive ALL or lymphoid blast phase of CML

Posted by on Jun 27, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if a combination of inotuzumab ozogamicin (InO; Besponsa) and bosutinib (Bo; Bosulif) was safe and effective in patients with relapsed/refractory (r/r) Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) or lymphoid blast phase (BP) chronic myeloid leukemia...

Read More

Comparing alectinib to ceritinib treatment for ALK-positive non-small-cell lung cancer that failed after crizotinib treatment

Comparing alectinib to ceritinib treatment for ALK-positive non-small-cell lung cancer that failed after crizotinib treatment

Posted by on May 30, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of ceritinib (Zykadia) and alectinib (Alecensa) in patients with ALK-positive non-small-cell lung cancer (NSCLC) who previously had a crizotinib (Xalkori) treatment failure. The data showed that both ceritinib and alectinib were effective in these patients. Some background Non-small-cell lung cancer...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Melanoma | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including melanoma to examine the safety and effectiveness of experimental drug avapritinib (Ayvakit). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Posted by on Apr 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia/lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor